報價延遲最少15分鐘:2026/09/19 11:49 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.13 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.64/-0.94
|
|
企業價值
316.03M
|
| 資產負債 |
|
每股賬面淨值
3.64
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
216.11M
|
|
每股收益
3.94
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada. |
